{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:57:33Z","timestamp":1787860653504,"version":"build-2784847793"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"National Science Centre, Poland","award":["2020\/39\/D\/NZ5\/02330"],"award-info":[{"award-number":["2020\/39\/D\/NZ5\/02330"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Commun Signal"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>A mutation in the BRAF (serine\/threonine-protein kinase B-raf) gene is most often responsible for the progression of melanoma. A breakthrough in its treatment was the application of BRAF and MEK (mitogen-activated protein kinase kinase) inhibitors. Unfortunately, the effectiveness of this therapy is limited due to rapidly emerging resistance to the drugs. We derived two melanoma cell lines resistant to vemurafenib (a BRAF inhibitor)\/cobimetinib (an MEK inhibitor). Due to the significant impact of invasion on cancer progression, we focused our further research on this process.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Cell migration and invasion were assessed via the scratch wound assay. Selected proteins\u2019 level as well as the activation of focal adhesion kinase (FAK) were evaluated using Western blotting. The expression of the selected genes was examined by qRT-PCR. The focal adhesions parameters, actin polymerization ratio, as well as YAP\/TAZ (Yes-associated protein\/transcriptional co-activator with PDZ-binding motif), invadopodia, and \u03b2 and \u03b3 actin localization were analyzed using confocal microscopy. The composition and activity of proteases secreted by cells were determined using a human protease array and gelatin zymography. In addition, cell adhesion and matrix metalloproteinase (MMP14) activity were assessed using appropriate assays.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Our analysis showed a greater capacity for migration and invasion of resistant melanoma cells compared to controls, as well as an increase in the level of RUNX2 (runt-related transcription factor 2). Moreover, examined cells exhibited higher adhesion to the surface and were more spread. These cells also formed more focal adhesions. Furthermore, we noticed an increased level of \u03b1-parvin and vinculin in resistant cells, as well as an elevated activation of FAK (focal adhesion kinase). Resistance was additionally accompanied by rearrangement of the actin cytoskeleton. Examined cells formed more stress fibers compared to control cells. YAP\/TAZ localization became much more nuclear in the resistant ones. The amount of invadopodia was increased, which was reflected by elevated secretion and activation of proteases, as well as altered expression of their inhibitors.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In summary, our study characterized a significantly more invasive phenotype of double-resistant cell lines compared to melanoma cells sensitive to BRAF and MEK inhibitors. Successful inhibition of this phenotype could result in more effective therapy and thus a better prognosis for patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12964-025-02452-0","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:35:02Z","timestamp":1761046502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Phenotype switching in highly invasive resistant to vemurafenib and cobimetinib melanoma cells"],"prefix":"10.1186","volume":"23","author":[{"given":"Aleksandra","family":"Simiczyjew","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Kot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Majkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Zi\u0119tek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rafa\u0142","family":"Matkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorota","family":"Nowak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"2452_CR1","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/J.HOC.2018.09.005","volume":"33","author":"RI Hartman","year":"2019","unstructured":"Hartman RI, Lin JY. Cutaneous melanoma-a review in detection, staging, and management. Hematol Oncol Clin North Am. 2019;33:25\u201338. https:\/\/doi.org\/10.1016\/J.HOC.2018.09.005.","journal-title":"Hematol Oncol Clin North Am"},{"key":"2452_CR2","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.3892\/IJO.2018.4287","volume":"52","author":"GC Leonardi","year":"2018","unstructured":"Leonardi GC, Falzone L, Salemi R, Zangh\u00ec A, Spandidos DA, Mccubrey JA, et al. Cutaneous melanoma: from pathogenesis to therapy (review). Int J Oncol. 2018;52:1071\u201380. https:\/\/doi.org\/10.3892\/IJO.2018.4287.","journal-title":"Int J Oncol"},{"key":"2452_CR3","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/nature00766","volume":"417","author":"H Davies","year":"2002","unstructured":"Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W, Davis N, Dicks E, Ewing R, Floyd Y, Gray K, Hall S, Hawes R, Hughes J, Kosmidou V, Menzies A, Mould C, Parker A, Stevens C, Watt S, Hooper S, Jayatilake H, Gusterson BA, Cooper C, Shipley J, Hargrave D, Pritchard-Jones K, Maitland N, Chenevix-Trench G, Riggins GJ, Bigner DD, Palmieri G, Cossu A, Flanagan A, Nicholson A, Ho JWC, Leung SY, Yuen ST, Weber BL, Seigler HF, Darrow TL, Paterson H, Wooster R, Stratton MR, Futreal PA. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949\u201354. https:\/\/doi.org\/10.1038\/nature00766.","journal-title":"Nature"},{"key":"2452_CR4","doi-asserted-by":"publisher","unstructured":"Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Grob JJ, Sileni VC, Lebbe C, Mandal\u00e0 M, Millward M, Arance A, Bondarenko I, a. JB, Haanen G, Hansson J, Utikal J, Ferraresi V, Kovalenko N, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, DeMarini DJ, Irani JG, Casey M, Ouellet D, Martin A-M, Le N, Patel K, Flaherty K. Combined BRAF and MEK Inhibition versus BRAF Inhibition alone in Melanoma, N. Engl. J Med. 2014;140929070023009. https:\/\/doi.org\/10.1056\/NEJMoa1406037.","DOI":"10.1056\/NEJMoa1406037"},{"key":"2452_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.21037\/atm.2016.06.07","volume":"4","author":"JL Manzano","year":"2016","unstructured":"Manzano JL, Layos L, Bug\u00e9s C, De los Llanos Gil M, Vila L, Mart\u00ednez-Balibrea E, Mart\u00ednez-Card\u00fas A. Resistant mechanisms to BRAF inhibitors in melanoma. Ann Transl Med. 2016;4:1\u20139. https:\/\/doi.org\/10.21037\/atm.2016.06.07.","journal-title":"Ann Transl Med"},{"key":"2452_CR6","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1517\/14656566.2016.1168806","volume":"17","author":"A Boespflug","year":"2016","unstructured":"Boespflug A, Thomas L. Cobimetinib and vemurafenib for the treatment of melanoma. Expert Opin Pharmacother. 2016;17:1005\u201311. https:\/\/doi.org\/10.1517\/14656566.2016.1168806.","journal-title":"Expert Opin Pharmacother"},{"key":"2452_CR7","doi-asserted-by":"publisher","DOI":"10.1186\/s12964-024-01788-3","author":"M Kot","year":"2024","unstructured":"Kot M, Simiczyjew A, W\u0105dzy\u0144ska J, Zi\u0119tek M, Matkowski R, Nowak D. Characterization of two melanoma cell lines resistant to BRAF\/MEK inhibitors (vemurafenib and cobimetinib). Cell Commun Signal. 2024. https:\/\/doi.org\/10.1186\/s12964-024-01788-3.","journal-title":"Cell Commun Signal"},{"key":"2452_CR8","unstructured":"Cellosaurus cell line WM9 (CVCL_6806). https:\/\/www.cellosaurus.org\/CVCL_6806"},{"key":"2452_CR9","unstructured":"Cellosaurus cell line Hs 294T (CVCL_0331). https:\/\/www.cellosaurus.org\/CVCL_0331"},{"key":"2452_CR10","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1109\/34.659930","volume":"20","author":"G Steger","year":"1998","unstructured":"Steger G. An unbiased detector of curvilinear structures. IEEE Trans Pattern Anal Mach Intell. 1998;20:113\u201325. https:\/\/doi.org\/10.1109\/34.659930.","journal-title":"IEEE Trans Pattern Anal Mach Intell"},{"key":"2452_CR11","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1186\/s12964-022-00871-x","volume":"20","author":"J Mazurkiewicz","year":"2022","unstructured":"Mazurkiewicz J, Simiczyjew A, Dratkiewicz E, Pietraszek-Gremplewicz K, Majkowski M, Kot M, Zi\u0119tek M, Matkowski R, Nowak D. Melanoma cells with diverse invasive potential differentially induce the activation of normal human fibroblasts. Cell Commun Signal. 2022;20:63. https:\/\/doi.org\/10.1186\/s12964-022-00871-x.","journal-title":"Cell Commun Signal"},{"key":"2452_CR12","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1016\/j.semcancer.2005.05.004","volume":"15","author":"HK Kleinman","year":"2005","unstructured":"Kleinman HK, Martin GR. Matrigel: basement membrane matrix with biological activity. Semin Cancer Biol. 2005;15:378\u201386. https:\/\/doi.org\/10.1016\/j.semcancer.2005.05.004.","journal-title":"Semin Cancer Biol"},{"key":"2452_CR13","doi-asserted-by":"publisher","unstructured":"McRee SK, Bayer AL, Pietruska J, Tsichlis PN, Hinds PW. AKT2 loss impairs BRAF-Mutant melanoma metastasis. Cancers (Basel). 2023;15. https:\/\/doi.org\/10.3390\/cancers15204958.","DOI":"10.3390\/cancers15204958"},{"key":"2452_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/J.CELLSIG.2021.110046","author":"YG Mishra","year":"2021","unstructured":"Mishra YG, Manavathi B. Focal adhesion dynamics in cellular function and disease. Cell Signal. 2021. https:\/\/doi.org\/10.1016\/J.CELLSIG.2021.110046.","journal-title":"Cell Signal"},{"key":"2452_CR15","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.diff.2013.02.003","volume":"86","author":"KC Rustad","year":"2013","unstructured":"Rustad KC, Wong VW, Gurtner GC. The role of focal adhesion complexes in fibroblast mechanotransduction during scar formation. Differentiation. 2013;86:87\u201391. https:\/\/doi.org\/10.1016\/j.diff.2013.02.003.","journal-title":"Differentiation"},{"key":"2452_CR16","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1152\/physrev.00018.2013","volume":"94","author":"L Blanchoin","year":"2014","unstructured":"Blanchoin L, Boujemaa-Paterski R, Sykes C, Plastino J. Actin dynamics, architecture, and mechanics in cell motility. Physiol Rev. 2014;94:235\u201363. https:\/\/doi.org\/10.1152\/physrev.00018.2013.","journal-title":"Physiol Rev"},{"key":"2452_CR17","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00018-005-5355-1","volume":"63","author":"JL Sepulveda","year":"2006","unstructured":"Sepulveda JL, Wu C. The Parvins. Cell Mol Life Sci. 2006;63:25\u201335. https:\/\/doi.org\/10.1007\/s00018-005-5355-1.","journal-title":"Cell Mol Life Sci"},{"key":"2452_CR18","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1083\/jcb.200703036","volume":"179","author":"JD Humphries","year":"2007","unstructured":"Humphries JD, Wang P, Streuli C, Geiger B, Humphries MJ, Ballestrem C. Vinculin controls focal adhesion formation by direct interactions with Talin and actin. J Cell Biol. 2007;179:1043\u201357. https:\/\/doi.org\/10.1083\/jcb.200703036.","journal-title":"J Cell Biol"},{"key":"2452_CR19","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13081871","author":"A Mousson","year":"2021","unstructured":"Mousson A, Legrand M, Steffan T, Vauchelles R, Carl P, Gies JP, et al. Inhibiting fak\u2013paxillin interaction reduces migration and invadopodia-mediated matrix degradation in metastatic melanoma cells. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13081871.","journal-title":"Cancers (Basel)"},{"key":"2452_CR20","doi-asserted-by":"publisher","first-page":"462","DOI":"10.15252\/embj.201592081","volume":"35","author":"MH Kim","year":"2016","unstructured":"Kim MH, Kim J, Hong H, Lee S, Lee J, Jung E, Kim J. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP \/ TAZ activation. EMBO J. 2016;35:462\u201378. https:\/\/doi.org\/10.15252\/embj.201592081.","journal-title":"EMBO J"},{"key":"2452_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21082746","author":"N Malek","year":"2020","unstructured":"Malek N, Mr\u00f3wczy\u0144ska E, Michrowska A, Mazurkiewicz E, Pavlyk I, Mazur AJ. Knockout of ACTB and ACTG1 with CRISPR\/Cas9(D10A) technique shows that non-muscle \u03b2 and \u03b3 actin are not equal in relation to human melanoma cells\u2019 motility and focal adhesion formation. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21082746.","journal-title":"Int J Mol Sci"},{"key":"2452_CR22","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.yexcr.2015.11.003","volume":"339","author":"A Simiczyjew","year":"2015","unstructured":"Simiczyjew A, Mazur AJ, Ampe C, Malicka-B\u0142aszkiewicz M, van Troys M, Nowak D. Active invadopodia of mesenchymally migrating cancer cells contain both \u03b2 and \u03b3 cytoplasmic actin isoforms, exp. Cell Res. 2015;339:206\u201319. https:\/\/doi.org\/10.1016\/j.yexcr.2015.11.003.","journal-title":"Cell Res"},{"key":"2452_CR23","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1242\/jcs.041970","volume":"122","author":"V Dugina","year":"2009","unstructured":"Dugina V, Zwaenepoel I, Gabbiani G, Cl\u00e9ment S, Chaponnier C. Beta and gamma-cytoplasmic actins display distinct distribution and functional diversity. J Cell Sci. 2009;122:2980\u20138. https:\/\/doi.org\/10.1242\/jcs.041970.","journal-title":"J Cell Sci"},{"key":"2452_CR24","doi-asserted-by":"publisher","DOI":"10.1007\/s00418-014-1199-9","author":"A Simiczyjew","year":"2014","unstructured":"Simiczyjew A, Mazur AJ, Popow-Wo\u017aniak A, Malicka-B\u0142aszkiewicz M, Nowak D. Effect of overexpression of \u03b2- and \u03b3-actin isoforms on actin cytoskeleton organization and migration of human colon cancer cells. Histochem Cell Biol. 2014. https:\/\/doi.org\/10.1007\/s00418-014-1199-9.","journal-title":"Histochem Cell Biol"},{"key":"2452_CR25","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.ejcb.2012.04.001","volume":"91","author":"H Sibony-Benyamini","year":"2012","unstructured":"Sibony-Benyamini H, Gil-Henn H. Invadopodia: the leading force. Eur J Cell Biol. 2012;91:896\u2013901. https:\/\/doi.org\/10.1016\/j.ejcb.2012.04.001.","journal-title":"Eur J Cell Biol"},{"key":"2452_CR26","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ejcb.2014.10.002","volume":"93","author":"E G\u00e9not","year":"2014","unstructured":"G\u00e9not E, Gligorijevic B. Invadosomes in their natural habitat. Eur J Cell Biol. 2014;93:367\u201379. https:\/\/doi.org\/10.1016\/j.ejcb.2014.10.002.","journal-title":"Eur J Cell Biol"},{"key":"2452_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejcb.2014.07.003","author":"BT Beaty","year":"2014","unstructured":"Beaty BT, Condeelis J. Digging a little deeper: the stages of invadopodium formation and maturation. Eur J Cell Biol. 2014. https:\/\/doi.org\/10.1016\/j.ejcb.2014.07.003.","journal-title":"Eur J Cell Biol"},{"key":"2452_CR28","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1016\/j.yexcr.2005.12.012","volume":"312","author":"ET Bowden","year":"2006","unstructured":"Bowden ET, Onikoyi E, Slack R, Myoui A, Yoneda T, Yamada KM, et al. Co-localization of cortactin and phosphotyrosine identifies active invadopodia in human breast cancer cells. Exp Cell Res. 2006;312:1240\u201353. https:\/\/doi.org\/10.1016\/j.yexcr.2005.12.012.","journal-title":"Exp Cell Res"},{"key":"2452_CR29","doi-asserted-by":"publisher","first-page":"23300","DOI":"10.1038\/S41598-025-06608-3","volume":"15","author":"J Hei","year":"2025","unstructured":"Hei J, Bai X, Wang J. Matrix metalloproteinases as diagnostic and prognostic biomarkers in skin cutaneous melanoma and squamous cell carcinoma. Sci Rep. 2025;15:23300. https:\/\/doi.org\/10.1038\/S41598-025-06608-3.","journal-title":"Sci Rep"},{"key":"2452_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/cells9051151","volume":"9","author":"S Napoli","year":"2020","unstructured":"Napoli S, Scuderi C, Gattuso G, Di Bella V, Candido S, Basile MS, Libra M, Falzone L. Functional roles of matrix metalloproteinases and their inhibitors in melanoma. Cells. 2020;9:1\u201323. https:\/\/doi.org\/10.3390\/cells9051151.","journal-title":"Cells"},{"key":"2452_CR31","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/j.semcancer.2010.05.002","volume":"20","author":"D Bourboulia","year":"2010","unstructured":"Bourboulia D, Stetler-Stevenson WG. Matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs): positive and negative regulators in tumor cell adhesion. Semin Cancer Biol. 2010;20:161\u20138. https:\/\/doi.org\/10.1016\/j.semcancer.2010.05.002.","journal-title":"Semin Cancer Biol"},{"key":"2452_CR32","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13236058","author":"V Patel","year":"2021","unstructured":"Patel V, Sz\u00e1sz I, Koroknai V, Kiss T, Bal\u00e1zs M. Molecular alterations associated with acquired drug resistance during combined treatment with Encorafenib and binimetinib in melanoma cell lines. Cancers (Basel). 2021. https:\/\/doi.org\/10.3390\/cancers13236058.","journal-title":"Cancers (Basel)"},{"key":"2452_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15252\/emmm.202115295","volume":"14","author":"S Diazzi","year":"2022","unstructured":"Diazzi S, Baeri A, Fassy J, Lecacheur M, Marin-Bejar O, Girard CA, Lefevre L, Lacoux C, Irondelle M, Mounier C, Truchi M, Couralet M, Ohanna M, Carminati A, Berestjuk I, Larbret F, Gilot D, Vassaux G, Marine J, Deckert M, Mari B, Tartare\u2010Deckert S. Blockade of the pro\u2010fibrotic reaction mediated by the miR\u2010143\/\u2010145 cluster enhances the responses to targeted therapy in melanoma. EMBO Mol Med. 2022;14:1\u201322. https:\/\/doi.org\/10.15252\/emmm.202115295.","journal-title":"EMBO Mol Med"},{"key":"2452_CR34","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1158\/2159-8290.CD-14-0293","volume":"5","author":"KHT Paraiso","year":"2015","unstructured":"Paraiso KHT, Das Thakur M, Fang B, Koomen JM, Fedorenko IV, John JK, et al. Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype. Cancer Discov. 2015;5:264\u201373. https:\/\/doi.org\/10.1158\/2159-8290.CD-14-0293.","journal-title":"Cancer Discov"},{"key":"2452_CR35","doi-asserted-by":"publisher","first-page":"1850","DOI":"10.1038\/ONC.2013.131","volume":"33","author":"A Vultur","year":"2014","unstructured":"Vultur A, Villanueva J, Krepler C, Rajan G, Chen Q, Xiao M, et al. MEK inhibition affects STAT3 signaling and invasion in human melanoma cell lines. Oncogene. 2014;33:1850\u201361. https:\/\/doi.org\/10.1038\/ONC.2013.131.","journal-title":"Oncogene"},{"key":"2452_CR36","doi-asserted-by":"publisher","first-page":"5937","DOI":"10.1158\/0008-5472.CAN-14-1174","volume":"74","author":"K Kemper","year":"2014","unstructured":"Kemper K, De Goeje PL, Peeper DS, Van Amerongen R. Phenotype switching: tumor cell plasticity as a resistance mechanism and target for therapy. Cancer Res. 2014;74:5937\u201341. https:\/\/doi.org\/10.1158\/0008-5472.CAN-14-1174.","journal-title":"Cancer Res"},{"key":"2452_CR37","doi-asserted-by":"publisher","first-page":"2571","DOI":"10.1038\/S41388-022-02266-1","volume":"41","author":"M Sala","year":"2022","unstructured":"Sala M, Allain N, Moreau M, Jabouille A, Henriet E, Abou-Hammoud A, Uguen A, Di-Tommaso S, Dourthe C, Raymond AA, Dupuy JW, Gerard E, Dugot-Senant N, Rousseau B, Merlio JP, Pham-Ledart A, Vergier B, Tartare-Deckert S, Moreau V. Saltel, discoidin domain receptor 2 orchestrates melanoma resistance combining phenotype switching and proliferation. Oncogene. 2022;41:2571\u201386. https:\/\/doi.org\/10.1038\/S41388-022-02266-1.","journal-title":"Oncogene"},{"key":"2452_CR38","doi-asserted-by":"publisher","first-page":"e0190834","DOI":"10.1371\/JOURNAL.PONE.0190834","volume":"13","author":"JC Cronin","year":"2018","unstructured":"Cronin JC, Loftus SK, Baxter LL, Swatkoski S, Gucek M, Pavan WJ. Identification and functional analysis of SOX10 phosphorylation sites in melanoma. PLoS ONE. 2018;13:e0190834. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0190834.","journal-title":"PLoS ONE"},{"key":"2452_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/S41467-022-28801-Y","author":"C Capparelli","year":"2022","unstructured":"Capparelli C, Purwin TJ, Glasheen MK, Caksa S, Tiago M, Wilski N, et al. Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma. Nat Commun. 2022. https:\/\/doi.org\/10.1038\/S41467-022-28801-Y.","journal-title":"Nat Commun"},{"key":"2452_CR40","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1016\/j.cellsig.2015.07.016","volume":"27","author":"D N\u00f6rz","year":"2015","unstructured":"N\u00f6rz D, Grottke A, Bach J, Herzberger C, Hofmann BT, Nashan B, et al. Discontinuing MEK inhibitors in tumor cells with an acquired resistance increases migration and invasion. Cell Signal. 2015;27:2191\u2013200. https:\/\/doi.org\/10.1016\/j.cellsig.2015.07.016.","journal-title":"Cell Signal"},{"key":"2452_CR41","doi-asserted-by":"publisher","first-page":"4619","DOI":"10.1242\/JCS.01481","volume":"117","author":"C Huang","year":"2004","unstructured":"Huang C, Jacobson K, Schaller MD. MAP kinases and cell migration. J Cell Sci. 2004;117:4619\u201328. https:\/\/doi.org\/10.1242\/JCS.01481.","journal-title":"J Cell Sci"},{"key":"2452_CR42","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.phrs.2016.07.017","volume":"111","author":"S Sandri","year":"2016","unstructured":"Sandri S, Faiao-Flores F, Tiago M, Pennacchi PC, Massaro RR, Alves-Fernandes DK, et al. Vemurafenib resistance increases melanoma invasiveness and modulates the tumor microenvironment by MMP-2 upregulation. Pharmacol Res. 2016;111:523\u201333. https:\/\/doi.org\/10.1016\/j.phrs.2016.07.017.","journal-title":"Pharmacol Res"},{"key":"2452_CR43","doi-asserted-by":"publisher","first-page":"1531","DOI":"10.1016\/J.CELLSIG.2012.03.015","volume":"24","author":"J Pribic","year":"2012","unstructured":"Pribic J, Brazill D. Paxillin phosphorylation and complexing with Erk and FAK are regulated by PLD activity in MDA-MB-231 cells. Cell Signal. 2012;24:1531\u201340. https:\/\/doi.org\/10.1016\/J.CELLSIG.2012.03.015.","journal-title":"Cell Signal"},{"key":"2452_CR44","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.canlet.2014.03.011","volume":"348","author":"RK Boregowda","year":"2014","unstructured":"Boregowda RK, Olabisi OO, Abushahba W, Jeong BS, Haenssen KK, Chen W, Chekmareva M, Lasfar A, Foran DJ, Goydos JS, Cohen-Solal KA. RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion. Cancer Lett. 2014;348:61\u201370. https:\/\/doi.org\/10.1016\/j.canlet.2014.03.011.","journal-title":"Cancer Lett"},{"key":"2452_CR45","doi-asserted-by":"publisher","DOI":"10.1186\/1476-4598-9-258","author":"SK Baniwal","year":"2010","unstructured":"Baniwal SK, Khalid O, Gabet Y, Shah RR, Purcell DJ, Mav D, et al. Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis. Mol Cancer. 2010. https:\/\/doi.org\/10.1186\/1476-4598-9-258.","journal-title":"Mol Cancer"},{"key":"2452_CR46","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS7110220","author":"M Deiana","year":"2018","unstructured":"Deiana M, Carbonare LD, Serena M, Cheri S, Parolini F, Gandini A, et al. New insights into the runt domain of RUNX2 in melanoma cell proliferation and migration. Cells. 2018. https:\/\/doi.org\/10.3390\/CELLS7110220.","journal-title":"Cells"},{"key":"2452_CR47","doi-asserted-by":"publisher","first-page":"29689","DOI":"10.18632\/oncotarget.8822","volume":"7","author":"RK Boregowda","year":"2016","unstructured":"Boregowda RK, Medina DJ, Markert E, Bryan MA, Chen W, Chen S, Rabkin A, Vido MJ, Gunderson SI, Chekmareva M, Foran DJ, Lasfar A, Goydos JS. Cohen-Solal, the transcription factor RUNX2 regulates receptor tyrosine kinase expression in melanoma. Oncotarget. 2016;7:29689\u2013707. https:\/\/doi.org\/10.18632\/oncotarget.8822.","journal-title":"Oncotarget"},{"key":"2452_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-015-0404-3","volume":"14","author":"KA Cohen-Solal","year":"2015","unstructured":"Cohen-Solal KA, Boregowda RK, Lasfar A. RUNX2 and the PI3K\/AKT axis reciprocal activation as a driving force for tumor progression. Mol Cancer. 2015;14:1\u201310. https:\/\/doi.org\/10.1186\/s12943-015-0404-3.","journal-title":"Mol Cancer"},{"key":"2452_CR49","doi-asserted-by":"publisher","unstructured":"Dratkiewicz E, Simiczyjew A, Pietraszek-Gremplewicz K, Mazurkiewicz J, Nowak D. Characterization of melanoma cell lines resistant to Vemurafenib and evaluation of their responsiveness to EGFR-and MET-inhibitor treatment. Int J Mol Sci. 2020;21. https:\/\/doi.org\/10.3390\/ijms21010113.","DOI":"10.3390\/ijms21010113"},{"key":"2452_CR50","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.pharmthera.2013.12.003","volume":"142","author":"J Zhang","year":"2014","unstructured":"Zhang J, Hochwald SN. The role of FAK in tumor metabolism and therapy. Pharmacol Ther. 2014;142:154\u201363. https:\/\/doi.org\/10.1016\/j.pharmthera.2013.12.003.","journal-title":"Pharmacol Ther"},{"key":"2452_CR51","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1242\/jcs.03314","volume":"120","author":"R Zaidel-Bar","year":"2007","unstructured":"Zaidel-Bar R, Milo R, Kam Z, Geiger B. A paxillin tyrosine phosphorylation switch regulates the assembly and form of cell-matrix adhesions. J Cell Sci. 2007;120:137\u201348. https:\/\/doi.org\/10.1242\/jcs.03314.","journal-title":"J Cell Sci"},{"key":"2452_CR52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7554\/eLife.63093","volume":"10","author":"R Dilshat","year":"2021","unstructured":"Dilshat R, Fock V, Kenny C, Gerritsen I, Lasseur RMJ, Travnickova J, Eichhoff O, Cerny P, M\u00f6ller K, Sigurbj\u00f6rnsd\u00f3ttir S, Kirty K, Einarsdottir B\u00d3, Cheng PF, Levesque M, Cornell RA, Patton EE, Larue L, De Tayrac M, Magn\u00fasd\u00f3ttir E, Ogmundsdottir MH, Steingr\u00edmsson E. Mitf reprograms the extracellular matrix and focal adhesion in melanoma. Elife. 2021;10:1\u201359. https:\/\/doi.org\/10.7554\/eLife.63093.","journal-title":"Elife"},{"key":"2452_CR53","doi-asserted-by":"publisher","DOI":"10.1038\/s41589-023-01353-y","author":"X Li","year":"2023","unstructured":"Li X, Combs JD, Salaita K, Shu X. Polarized focal adhesion kinase activity within a focal adhesion during cell migration. Nat Chem Biol. 2023. https:\/\/doi.org\/10.1038\/s41589-023-01353-y.","journal-title":"Nat Chem Biol"},{"key":"2452_CR54","doi-asserted-by":"publisher","DOI":"10.1038\/S41419-022-04502-8","author":"G Del Mistro","year":"2022","unstructured":"Del Mistro G, Riemann S, Schindler S, Beissert S, Kontermann RE, Ginolhac A, et al. Focal adhesion kinase plays a dual role in TRAIL resistance and metastatic outgrowth of malignant melanoma. Cell Death Dis. 2022. https:\/\/doi.org\/10.1038\/S41419-022-04502-8.","journal-title":"Cell Death Dis"},{"key":"2452_CR55","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fcell.2022.1040311","volume":"10","author":"Z Zhang","year":"2022","unstructured":"Zhang Z, Li J, Jiao S, Han G, Zhu J, Liu T. Functional and clinical characteristics of focal adhesion kinases in cancer progression. Front Cell Dev Biol. 2022;10:1\u201323. https:\/\/doi.org\/10.3389\/fcell.2022.1040311.","journal-title":"Front Cell Dev Biol"},{"key":"2452_CR56","doi-asserted-by":"publisher","first-page":"6039","DOI":"10.1158\/1078-0432.CCR-19-2773","volume":"26","author":"C Marusak","year":"2020","unstructured":"Marusak C, Thakur V, Li Y, Freitas JT, Zmina PM, Thakur VS, Chang M, Gao M, Tan J, Xiao M, Lu Y, Mills GB, Flaherty K, Frederick DT, Miao B, Sullivan RJ, Moll T, Boland GM, Herlyn M, Zhang G, Bedogni B. Targeting extracellular matrix remodeling restores BRAF inhibitor sensitivity in BRAFi-resistant melanoma, clin. Cancer Res. 2020;26:6039\u201350. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-2773.","journal-title":"Cancer Res"},{"key":"2452_CR57","doi-asserted-by":"publisher","unstructured":"Murali VS, Rajendran D, Isogai T, DeBerardinis R.J., Danuser G. RhoA activation promotes glucose uptake to elevate proliferation in MAPK inhibitor resistant melanoma cells. BioRxiv. 2024;20240109574940. https:\/\/doi.org\/10.1101\/2024.01.09.574940.","DOI":"10.1101\/2024.01.09.574940"},{"key":"2452_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241813785","author":"BM Foda","year":"2023","unstructured":"Foda BM, Neubig RR. Role of Rho\/MRTF in aggressive Vemurafenib-resistant murine melanomas and immune checkpoint upregulation. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241813785.","journal-title":"Int J Mol Sci"},{"key":"2452_CR59","doi-asserted-by":"publisher","first-page":"30112","DOI":"10.18632\/oncotarget.15618","volume":"8","author":"SJ Wen","year":"2017","unstructured":"Wen SJ, Zhang W, Ni NN, Wu Q, Wang XP, Lin YK, Sun JF. Expression of Rho GTPases family in melanoma cells and its influence on cytoskeleton and migration. Oncotarget. 2017;8:30112\u201322. https:\/\/doi.org\/10.18632\/oncotarget.15618.","journal-title":"Oncotarget"},{"key":"2452_CR60","doi-asserted-by":"publisher","DOI":"10.1186\/S13046-022-02354-W","author":"R Loria","year":"2022","unstructured":"Loria R, Laquintana V, Scalera S, Fraioli R, Caprara V, Falcone I, et al. SEMA6A\/RhoA\/YAP axis mediates tumor-stroma interactions and prevents response to dual BRAF\/MEK inhibition in BRAF-mutant melanoma. J Exp Clin Cancer Res. 2022. https:\/\/doi.org\/10.1186\/S13046-022-02354-W.","journal-title":"J Exp Clin Cancer Res"},{"key":"2452_CR61","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1016\/j.celrep.2016.04.073","volume":"15","author":"H Lu","year":"2016","unstructured":"Lu H, Liu S, Zhang G, Kwong LN, Zhu Y, Miller JP, et al. Oncogenic BRAF-mediated melanoma cell invasion. Cell Rep. 2016;15:2012\u201324. https:\/\/doi.org\/10.1016\/j.celrep.2016.04.073.","journal-title":"Cell Rep"},{"key":"2452_CR62","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.20892\/j.issn.2095-3941.2020.0294","volume":"19","author":"J Shen","year":"2022","unstructured":"Shen J, Yang J, Sang L, Sun R, Bai W, Wang C, Sun Y, Sun J. PYK2 mediates the BRAF inhibitor (vermurafenib)-induced invadopodia formation and metastasis in melanomas. Cancer Biol Med. 2022;19:1211\u201323. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2020.0294.","journal-title":"Cancer Biol Med"},{"key":"2452_CR63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.tcb.2018.11.006","volume":"29","author":"R Ferrari","year":"2019","unstructured":"Ferrari R, Infante E, Chavrier P. Nucleus\u2013invadopodia duo during cancer invasion. Trends Cell Biol. 2019;29:93\u20136. https:\/\/doi.org\/10.1016\/j.tcb.2018.11.006.","journal-title":"Trends Cell Biol"},{"key":"2452_CR64","doi-asserted-by":"publisher","DOI":"10.1126\/SCISIGNAL.AAO0422","author":"R Tripathi","year":"2018","unstructured":"Tripathi R, Fiore LS, Richards DL, Yang Y, Liu J, Wang C, et al. Abl and Arg mediate cysteine cathepsin secretion to facilitate melanoma invasion and metastasis. Sci Signal. 2018. https:\/\/doi.org\/10.1126\/SCISIGNAL.AAO0422.","journal-title":"Sci Signal"},{"key":"2452_CR65","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.2741\/3393","volume":"14","author":"L Paraoan","year":"2009","unstructured":"Paraoan L, Gray D, Hiscott P, Garcia-Finana M, Lane B, Damato B, Grierson I. Cathepsin S and its inhibitor Cystatin C: imbalance in uveal melanoma, front. Biosci (Landmark Ed. 2009;14:2504\u201313. https:\/\/doi.org\/10.2741\/3393.","journal-title":"Biosci (Landmark Ed"},{"key":"2452_CR66","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1007\/S004030050012","volume":"292","author":"L Kozlowski","year":"2000","unstructured":"Kozlowski L, Wojtukiewicz MZ, Ostrowska H. Cathepsin a activity in primary and metastatic human melanocytic tumors. Arch Dermatol Res. 2000;292:68\u201371. https:\/\/doi.org\/10.1007\/S004030050012.","journal-title":"Arch Dermatol Res"},{"key":"2452_CR67","first-page":"370","volume":"104","author":"L Zhu","year":"2013","unstructured":"Zhu L, Wada M, Usagawa Y, Yasukochi Y, Yokoyama A, Wada N, Sakamoto M, Maekawa T, Miyazaki R, Yonenaga E, Kiyomatsu M, Murata M, Furue M. Overexpression of cathepsin D in malignant melanoma. Fukuoka Igaku Zasshi. 2013;104:370\u20135. https:\/\/pubmed.ncbi.nlm.nih.gov\/24511668\/. accessed November 3, 2024.","journal-title":"Fukuoka Igaku Zasshi"},{"key":"2452_CR68","doi-asserted-by":"publisher","first-page":"10849","DOI":"10.1158\/0008-5472.CAN-07-1791","volume":"67","author":"JS Blackburn","year":"2007","unstructured":"Blackburn JS, Rhodes CH, Coon CI, Brinckerhoff CE. RNA interference inhibition of matrix metalloproteinase-1 prevents melanoma metastasis by reducing tumor collagenase activity and angiogenesis. Cancer Res. 2007;67:10849\u201358. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-1791.","journal-title":"Cancer Res"},{"key":"2452_CR69","doi-asserted-by":"publisher","first-page":"4237","DOI":"10.1038\/ONC.2009.272","volume":"28","author":"JS Blackburn","year":"2009","unstructured":"Blackburn JS, Liu I, Coon CI, Brinckerhoff CE. A matrix metalloproteinase-1\/protease activated receptor-1 signaling axis promotes melanoma invasion and metastasis. Oncogene. 2009;28:4237\u201348. https:\/\/doi.org\/10.1038\/ONC.2009.272.","journal-title":"Oncogene"},{"key":"2452_CR70","doi-asserted-by":"publisher","first-page":"3145","DOI":"10.1158\/0008-5472.CAN-15-2511","volume":"76","author":"E Shoshan","year":"2016","unstructured":"Shoshan E, Braeuer RR, Kamiya T, Mobley AK, Huang L, Vasquez ME, et al. NFAT1 directly regulates IL8 and MMP3 to promote melanoma tumor growth and metastasis. Cancer Res. 2016;76:3145\u201355. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2511.","journal-title":"Cancer Res"},{"key":"2452_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/J.PRP.2020.153276","author":"G Pampalakis","year":"2021","unstructured":"Pampalakis G, Zingkou E, Zoumpourlis V, Sotiropoulou G. Ectopic expression of KLK6 in MDA-MB-435 melanoma cells reduces tumorigenicity in vivo. Pathol Res Pract. 2021. https:\/\/doi.org\/10.1016\/J.PRP.2020.153276.","journal-title":"Pathol Res Pract"},{"key":"2452_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3389\/fmolb.2022.864302","volume":"9","author":"JE Fromme","year":"2022","unstructured":"Fromme JE, Zigrino P. The role of extracellular matrix remodeling in skin tumor progression and therapeutic resistance. Front Mol Biosci. 2022;9:1\u201315. https:\/\/doi.org\/10.3389\/fmolb.2022.864302.","journal-title":"Front Mol Biosci"},{"key":"2452_CR73","doi-asserted-by":"publisher","first-page":"26411","DOI":"10.1074\/jbc.M001270200","volume":"275","author":"Z Wang","year":"2000","unstructured":"Wang Z, Juttermann R, Soloway PD. TIMP-2 is required for efficient activation of proMMP-2 in vivo. J Biol Chem. 2000;275:26411\u20135. https:\/\/doi.org\/10.1074\/jbc.M001270200.","journal-title":"J Biol Chem"},{"key":"2452_CR74","doi-asserted-by":"publisher","first-page":"21056","DOI":"10.1074\/jbc.274.30.21056","volume":"274","author":"P Kurschat","year":"1999","unstructured":"Kurschat P, Zigrino P, Nischt R, Breitkopf K, Steurer P, Klein CE, Krieg T, Mauch C. Tissue inhibitor of matrix metalloproteinase-2 regulates matrix metalloproteinase-2 activation by modulation of membrane-type 1 matrix metalloproteinase activity in high and low invasive melanoma cell lines. J Biol Chem. 1999;274:21056\u201362. https:\/\/doi.org\/10.1074\/jbc.274.30.21056.","journal-title":"J Biol Chem"},{"key":"2452_CR75","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/985132","author":"J Sun","year":"2010","unstructured":"Sun J. Matrix metalloproteinases and tissue inhibitor of metalloproteinases are essential for the inflammatory response in cancer cells. J Signal Transduct. 2010. https:\/\/doi.org\/10.1155\/2010\/985132.","journal-title":"J Signal Transduct"},{"key":"2452_CR76","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1038\/sj.bjc.6606017","volume":"104","author":"JW Kornfeld","year":"2011","unstructured":"Kornfeld JW, Meder S, Wohlberg M, Friedrich RE, Rau T, Riethdorf L, L\u00f6ning T, Pantel K, Riethdorf S. Overexpression of TACE and TIMP3 mRNA in head and neck cancer: association with tumour development and progression. Br J Cancer. 2011;104:138\u201345. https:\/\/doi.org\/10.1038\/sj.bjc.6606017.","journal-title":"Br J Cancer"},{"key":"2452_CR77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25063191","author":"WT Lee","year":"2024","unstructured":"Lee WT, Wu PY, Cheng YM, Huang YF. Tissue inhibitor of metalloproteinase 3: unravelling its biological function and significance in oncology. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms25063191.","journal-title":"Int J Mol Sci"},{"key":"2452_CR78","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1038\/jid.2008.323","volume":"129","author":"U Anderegg","year":"2009","unstructured":"Anderegg U, Eichenberg T, Parthaune T, Haiduk C, Saalbach A, Milkova L, Ludwig A, Grosche J, Averbeck M, Gebhardt C, Voelcker V, Sleeman JP, Simon JC. ADAM10 is the constitutive functional Sheddase of CD44 in human melanoma cells. J Invest Dermatol. 2009;129:1471\u201382. https:\/\/doi.org\/10.1038\/jid.2008.323.","journal-title":"J Invest Dermatol"},{"key":"2452_CR79","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/35010517","volume":"2","author":"DJ Sieg","year":"2000","unstructured":"Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, et al. Fak integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol. 2000;2:249\u201356. https:\/\/doi.org\/10.1038\/35010517.","journal-title":"Nat Cell Biol"},{"key":"2452_CR80","doi-asserted-by":"publisher","DOI":"10.1186\/bcr2360","author":"MK Wendt","year":"2009","unstructured":"Wendt MK, Schiemann WP. Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-\u03b2 signaling and metastasis. Breast Cancer Res. 2009. https:\/\/doi.org\/10.1186\/bcr2360.","journal-title":"Breast Cancer Res"},{"key":"2452_CR81","doi-asserted-by":"publisher","DOI":"10.4161\/tisb.26845","author":"H You","year":"2013","unstructured":"You H, Lei P, Andreadis ST. JNK is a novel regulator of intercellular adhesion. Tissue Barriers. 2013. https:\/\/doi.org\/10.4161\/tisb.26845.","journal-title":"Tissue Barriers"},{"key":"2452_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21061913","author":"A Mart\u00ednez-Lim\u00f3n","year":"2020","unstructured":"Mart\u00ednez-Lim\u00f3n A, Joaquin M, Caballero M, Posas F, de Nadal E. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. 2020. https:\/\/doi.org\/10.3390\/ijms21061913.","journal-title":"Int J Mol Sci"},{"key":"2452_CR83","unstructured":"Toto\u0144 E, Rybczy\u0144ska. The characteristics of focal adhesion kinase (FAK) and its role in carcinogenesis. 2007;61:303-9. https:\/\/www.phmd.pl\/pub\/phmd\/vol_61\/10441.pdf"},{"key":"2452_CR84","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1274209","author":"HH Hu","year":"2024","unstructured":"Hu HH, Wang SQ, Shang HL, Lv HF, Chen BB, Gao SG, et al. Roles and inhibitors of FAK in cancer: current advances and future directions. Front Pharmacol. 2024. https:\/\/doi.org\/10.3389\/fphar.2024.1274209.","journal-title":"Front Pharmacol"},{"key":"2452_CR85","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1093\/jmcb\/mjw036","volume":"8","author":"D Huang","year":"2016","unstructured":"Huang D, Li X, Sun L, Huang P, Ying H, Wang H, et al. Regulation of hippo signalling by p38 signalling. J Mol Cell Biol. 2016;8:328\u201337. https:\/\/doi.org\/10.1093\/jmcb\/mjw036.","journal-title":"J Mol Cell Biol"},{"key":"2452_CR86","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2014.07.034","author":"VA Codelia","year":"2014","unstructured":"Codelia VA, Sun G, Irvine KD. Regulation of YAP by mechanical strain through Jnk and Hippo signaling. Curr Biol. 2014. https:\/\/doi.org\/10.1016\/j.cub.2014.07.034.","journal-title":"Curr Biol"},{"key":"2452_CR87","doi-asserted-by":"publisher","first-page":"6433","DOI":"10.1007\/s11033-022-07457-3","volume":"49","author":"S Binay","year":"2022","unstructured":"Binay S, Kaptan E. Transcription factor Runx2 changes the expression of some matricellular proteins in metastatic breast cancer cells. Mol Biol Rep. 2022;49:6433\u201341. https:\/\/doi.org\/10.1007\/s11033-022-07457-3.","journal-title":"Mol Biol Rep"},{"key":"2452_CR88","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1159\/000492872","volume":"49","author":"H Lu","year":"2018","unstructured":"Lu H, Jiang T, Ren K, Li ZL, Ren J, Wu G, Han X. RUNX2 plays an oncogenic role in esophageal carcinoma by activating the PI3K\/AKT and ERK signaling pathways. Cell Physiol Biochem. 2018;49:217\u201325. https:\/\/doi.org\/10.1159\/000492872.","journal-title":"Cell Physiol Biochem"},{"key":"2452_CR89","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10495-017-1394-y","volume":"22","author":"J Dewangan","year":"2017","unstructured":"Dewangan J, Tandon D, Srivastava S, Verma AK, Yapuri A, Rath SK. Novel combination of salinomycin and resveratrol synergistically enhances the anti-proliferative and pro-apoptotic effects on human breast cancer cells. Apoptosis. 2017;22:1246\u201359. https:\/\/doi.org\/10.1007\/s10495-017-1394-y.","journal-title":"Apoptosis"},{"key":"2452_CR90","doi-asserted-by":"publisher","first-page":"1784","DOI":"10.1002\/jcp.24339","volume":"228","author":"S Pande","year":"2013","unstructured":"Pande S, Browne G, Padmanabhan S, Zaidi SK, Lian JB, van Wijnen AJ, et al. Oncogenic cooperation between PI3K\/Akt signaling and transcription factor Runx2 promotes the invasive properties of metastatic breast cancer cells. J Cell Physiol. 2013;228:1784\u201392. https:\/\/doi.org\/10.1002\/jcp.24339.","journal-title":"J Cell Physiol"},{"key":"2452_CR91","doi-asserted-by":"publisher","first-page":"11371","DOI":"10.2147\/CMAR.S274058","volume":"12","author":"J Liu","year":"2020","unstructured":"Liu J, Yu X, Liu B, Yu H, Li Z. Phosphorylated mapk14 promotes the proliferation and migration of bladder cancer cells by maintaining runx2 protein abundance. Cancer Manag Res. 2020;12:11371\u201382. https:\/\/doi.org\/10.2147\/CMAR.S274058.","journal-title":"Cancer Manag Res"},{"key":"2452_CR92","doi-asserted-by":"publisher","first-page":"37335","DOI":"10.1074\/jbc.M111.256156","volume":"286","author":"YL Hsu","year":"2011","unstructured":"Hsu YL, Huang MS, Yang CJ, Hung JY, Wu LY, Kuo PL. Lung tumor-associated osteoblast-derived bone morphogenetic protein-2 increased epithelial-to-mesenchymal transition of cancer by Runx2\/Snail signaling pathway. J Biol Chem. 2011;286:37335\u201346. https:\/\/doi.org\/10.1074\/jbc.M111.256156.","journal-title":"J Biol Chem"},{"key":"2452_CR93","doi-asserted-by":"publisher","DOI":"10.15252\/MSB.20145877","author":"M Fallahi-Sichani","year":"2015","unstructured":"Fallahi-Sichani M, Moerke NJ, Niepel M, Zhang T, Gray NS, Sorger PK. Systematic analysis of BRAF(V600E) melanomas reveals a role for JNK\/c-Jun pathway in adaptive resistance to drug-induced apoptosis. Mol Syst Biol. 2015. https:\/\/doi.org\/10.15252\/MSB.20145877.","journal-title":"Mol Syst Biol"},{"key":"2452_CR94","doi-asserted-by":"publisher","unstructured":"Riordan JD, Nathanson TA, Varzavand A, Hawkins AA, Peplinski RM, Hannan EC, Bibeau FA, Freesmeier NJ, Jilek MC, Coma S, Pachter JA, Dupuy AJ, Stipp CS. A critical role of FAK signaling in Rac1-driven melanoma cell resistance to MAPK pathway Inhibition. 2024. https:\/\/doi.org\/10.1101\/2024.12.22.629990.","DOI":"10.1101\/2024.12.22.629990"}],"container-title":["Cell Communication and Signaling"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12964-025-02452-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12964-025-02452-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T00:03:56Z","timestamp":1761091436000},"score":1,"resource":{"primary":{"URL":"https:\/\/biosignaling.biomedcentral.com\/articles\/10.1186\/s12964-025-02452-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":94,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["2452"],"URL":"https:\/\/doi.org\/10.1186\/s12964-025-02452-0","relation":{},"ISSN":["1478-811X"],"issn-type":[{"value":"1478-811X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"449"}}